Browsing Tag
Kate Haviland
1 post
Sanofi’s $9.5bn buyout of Blueprint Medicines signals high-stakes immunology expansion
Sanofi’s $9.5B Blueprint Medicines acquisition strengthens its rare disease pipeline with Ayvakit and signals deeper investment in immunology.